CENTRAL DISTRICT, Hong Kong
- Oct. 6, 2020
-- 1Globe Biomedical's conference call will be held at the company's head office on Wednesday 28th October and will start at 5:00pm local time.
1Globe Biomedical's Chief Executive Officer commented on the upcoming financial conference saying "2020 has been a crazy year, a devastating year for some so there will be a lot of talking points. The all-round performance of the business this year has shown the key qualities of 1Globe Biomedical. We have continued to expand our commercial portfolio with investment in medical technology and research, and we will continue to do so."
1Globe Biomedical's Chief Executive Officer also added "These tough times present new opportunities for us to strengthen our leadership in the field of medical research and immunotherapy and to continue to explore the broader immunology sector, with the potential to deliver increased value to shareholders and the patients we serve."
About Us - 1Globe Biomedical
1Globe Biomedical is a clinical stage biotechnology company pioneering the development of receptor T (1BioCARs™) therapies for cancer. Led by a world-class management team with significant experience in cell therapy, we are developing a pipeline of "off-the-shelf"
receptor T cell therapy candidates with the goal of delivering readily available cell therapy faster, more reliably and at greater scale to more patients.http://1globe-biomedical.com/about-us/history/index.html